Branchoria Fallacy Lab Fallacy Lab

Clearer thinking about bad arguments, weak evidence and persuasive mistakes.

Within Novelty

When New Treatments Outrun the Evidence

A new treatment can be promising without yet proving that it helps patients more than existing care.

On this page

  • Why approval is not the same as proven superiority
  • How trials, reversals, and standard care comparisons change the claim
  • Questions patients and readers can ask before accepting new is better claims
Preview for When New Treatments Outrun the Evidence

Introduction

The appeal to novelty becomes especially consequential in medicine because the stakes are unusually high. A new drug, device, or procedure can be genuinely innovative, yet innovation alone does not show that patients will live longer, feel better, function better, or experience fewer harms than they would with existing care. The central proof gap is the distance between a treatment being new and a treatment being demonstrably superior.

Medical Proof illustration 1 This distinction matters because modern regulatory systems often allow promising therapies to reach patients before every question has been answered. Early access can save lives, particularly for serious diseases with limited options. At the same time, history shows that some interventions that looked promising at first later failed to deliver meaningful patient benefits when tested more rigorously. The logical error occurs when “newly available” is treated as evidence of “better than current care” without the comparisons needed to support that conclusion. [U.S]fda.govtable surrogate endpoints were basis drug approval or licensureTable of Surrogate Endpoints That Were the Basis of Drug…29 Apr 2026 — This surrogate endpoint table includes surrogate endpoints that…. Food and Drug Administration [2U.S. Food and Drug Administration]fda.govaccelerated approval programU.S. Food and Drug AdministrationAccelerated Approval Program15 May 2026 — To allow for earlier approval of drugs that treat serious cond…Published: May 2026

Why Approval Is Not the Same as Proven Superiority

Many people assume that regulatory approval means a treatment has been proven better than existing alternatives. In reality, approval and superiority are different claims.

Approval generally means regulators have concluded that a product’s benefits outweigh its risks for a specific use based on available evidence. In some circumstances, especially for serious diseases, approval may be granted using evidence that predicts benefit rather than directly demonstrating it. The US Food and Drug Administration’s accelerated approval pathway, for example, allows approval based on a surrogate endpoint—a laboratory measurement, imaging result, or other marker thought to predict patient benefit but not itself a direct measure of how patients feel, function, or survive. [U.S]fda.govtable surrogate endpoints were basis drug approval or licensureTable of Surrogate Endpoints That Were the Basis of Drug…29 Apr 2026 — This surrogate endpoint table includes surrogate endpoints that…. Food and Drug Administration [2U.S. Food and Drug Administration]fda.govaccelerated approval programU.S. Food and Drug AdministrationAccelerated Approval Program15 May 2026 — To allow for earlier approval of drugs that treat serious cond…Published: May 2026

A cancer drug illustrates the distinction. If a treatment shrinks tumours, that may be encouraging. However, tumour shrinkage is not identical to proving that patients live longer or enjoy a better quality of life. The treatment may eventually show those benefits, but the evidence must still be gathered. [White & Case]whitecase.comaccelerated approval confirmatory trials requirement may further complicate lifeWhite & CaseAccelerated Approval confirmatory trials requirement may…14 Aug 2025 — Accelerated Approval allows the FDA to approve drug… [National Center for Health Research]center4research.orgNational Center for Health ResearchFDA Accelerated Approval Pathway: Controversies and…Accelerated approval is usually based on change…

The appeal to novelty enters when advocates move from “this treatment has been approved” to “this treatment is therefore better than standard care”. Approval may justify access. It does not automatically establish superiority.

The Problem of Surrogate Measures

Medicine frequently relies on measurements that can be observed earlier than final patient outcomes. Blood pressure, cholesterol levels, tumour response, and laboratory markers can all provide useful information. Yet a marker that improves does not always guarantee that patients experience the outcomes they actually care about. [U.S]fda.govtable surrogate endpoints were basis drug approval or licensureTable of Surrogate Endpoints That Were the Basis of Drug…29 Apr 2026 — This surrogate endpoint table includes surrogate endpoints that…. Food and Drug Administration [2U.S. Food and Drug Administration]fda.govaccelerated approval programU.S. Food and Drug AdministrationAccelerated Approval Program15 May 2026 — To allow for earlier approval of drugs that treat serious cond…Published: May 2026

Surrogate endpoints exist because waiting for definitive outcomes can take years. The trade-off is uncertainty. Regulators, clinicians, and patients may accept that uncertainty when the potential benefits are substantial, but accepting uncertainty is different from pretending it does not exist. [U.S]fda.govtable surrogate endpoints were basis drug approval or licensureTable of Surrogate Endpoints That Were the Basis of Drug…29 Apr 2026 — This surrogate endpoint table includes surrogate endpoints that…. Food and Drug Administration [White & Case]whitecase.comaccelerated approval confirmatory trials requirement may further complicate lifeWhite & CaseAccelerated Approval confirmatory trials requirement may…14 Aug 2025 — Accelerated Approval allows the FDA to approve drug…

FDA Drug Info Rounds, July 2012: Accelerated Approval Program

Channel: U.S. Food and Drug Administration · Views: 19.1K · Uploaded: July 2012 · Length: 3 minutes 44 seconds

Open on YouTube

How Trials, Reversals, and Standard-Care Comparisons Change the Claim

The strongest evidence that a new treatment is genuinely better usually comes from direct comparison with the current standard of care.

A treatment may appear impressive in an early study if patients improve after receiving it. Yet many illnesses fluctuate naturally, and patients often improve for reasons unrelated to the intervention. Randomised controlled trials help address these problems by comparing outcomes between groups and reducing bias.

The key question is not whether the new treatment works in isolation. The key question is whether it works better than what patients would otherwise receive.

Why Direct Comparisons Matter

A new therapy can outperform a placebo while still offering little advantage over established treatment. Conversely, it may provide similar effectiveness but fewer side effects, lower costs, or greater convenience. Without direct comparison, claims of superiority remain speculative. Regulatory and scientific guidance frequently treats active-comparator superiority trials as particularly strong evidence when the objective is to demonstrate that a new option improves on existing care. [PMC]pmc.ncbi.nlm.nih.govPMCClinical Benefit and Regulatory Outcomes of Cancer Drugs…by ITT Liu · 2024 · Cited by 135 — The US Food and Drug Administration's (…

This is where many new-is-better claims become vulnerable. Marketing language often highlights innovation, mechanism, or technological sophistication, while the more important comparative questions receive less attention.

Medical Reversals: When Better Evidence Changes the Story

Medicine also provides a cautionary record of interventions that initially appeared beneficial but later failed under stronger testing.

Researchers use the term medical reversal for situations in which a widely adopted practice is later shown through better evidence to be ineffective or less beneficial than previously believed. Studies examining the medical literature have identified hundreds of such reversals across different areas of healthcare. [NBER]nber.orgIntroduction to a New…by H Bolder · 2019 · Cited by 1 — A “medical reversal” occurs when new evidence (usually from a high-quality RCT… [PMC]pmc.ncbi.nlm.nih.govPMCClinical Benefit and Regulatory Outcomes of Cancer Drugs…by ITT Liu · 2024 · Cited by 135 — The US Food and Drug Administration's (… [Mayo Clinic Proceedings]mayoclinicproceedings.orgThis investigation sheds light on low-value practices.Read moreMayo Clinic ProceedingsA Decade of Reversal: An Analysis of 146 Contradicted…by V Prasad · 2013 · Cited by 470 — The reversal of estab…

The existence of medical reversals does not mean that medical progress is an illusion. In fact, reversals demonstrate science working as intended: claims are continuously tested against stronger evidence. The lesson for the appeal to novelty is different. Early enthusiasm is not proof. A promising mechanism, exciting preliminary result, or new technology can all fail when subjected to rigorous comparison. PMC [Mayo Clinic Proceedings]mayoclinicproceedings.orgThis investigation sheds light on low-value practices.Read moreMayo Clinic ProceedingsA Decade of Reversal: An Analysis of 146 Contradicted…by V Prasad · 2013 · Cited by 470 — The reversal of estab…

Medical Proof illustration 2

Confirmatory Trials and the Remaining Uncertainty

Accelerated approval systems are designed around the idea that some uncertainty is acceptable temporarily if patients gain earlier access to potentially valuable therapies. The bargain is that confirmatory trials must later verify whether the expected benefits actually occur. [U.S]fda.govtable surrogate endpoints were basis drug approval or licensureTable of Surrogate Endpoints That Were the Basis of Drug…29 Apr 2026 — This surrogate endpoint table includes surrogate endpoints that…. Food and Drug Administration [Food and Drug]fdli.orgFood and Drug Law Institute (FDLI)The Accelerated Approval Program: Desiderata for a…by O Robles — Using a surrogate or intermediate c… Law Institute (FDLI

Evidence from analyses of accelerated approvals shows why those confirmatory studies matter. Some approved treatments later demonstrate meaningful clinical benefits, while others fail to confirm the hoped-for advantages or are eventually withdrawn. Studies of cancer-drug approvals have found substantial variation between early promise and later confirmation of patient benefit. PMC [AACR]aacr.orgFewer Than Half of Accelerated Approval Drugs Showed…Apr 7, 2024 — 63% were converted to regular approval even though only 43% demonst…

The logical point is straightforward: a treatment can be promising enough to justify use while still lacking proof that it is superior. Those are different evidential standards.

Medical Proof illustration 3

Questions Patients and Readers Can Ask Before Accepting New-Is-Better Claims

When confronted with claims about a breakthrough treatment, a few questions can help separate evidence from novelty-driven persuasion.

What outcome improved?

Did the treatment improve a laboratory value or imaging result, or did it improve outcomes that matter directly to patients, such as survival, symptoms, mobility, or quality of life? [U.S]fda.govtable surrogate endpoints were basis drug approval or licensureTable of Surrogate Endpoints That Were the Basis of Drug…29 Apr 2026 — This surrogate endpoint table includes surrogate endpoints that…. Food and Drug Administration [2U.S. Food and Drug Administration]fda.govaccelerated approval programU.S. Food and Drug AdministrationAccelerated Approval Program15 May 2026 — To allow for earlier approval of drugs that treat serious cond…Published: May 2026

What was it compared against?

Was the treatment tested only against placebo, or against the current standard of care? A superiority claim requires an appropriate comparison. [PMC]pmc.ncbi.nlm.nih.govPMCClinical Benefit and Regulatory Outcomes of Cancer Drugs…by ITT Liu · 2024 · Cited by 135 — The US Food and Drug Administration's (…

How strong is the evidence?

Is the claim based on early observational findings, a small trial, or multiple large randomised studies? Evidence quality matters as much as the result itself. [PMC]pmc.ncbi.nlm.nih.govPMCClinical Benefit and Regulatory Outcomes of Cancer Drugs…by ITT Liu · 2024 · Cited by 135 — The US Food and Drug Administration's (…

[Are confirmatory studies complete?]fda.govU.S. Food and Drug AdministrationProject ConfirmAccelerated approval allows for earlier access to drugs and biologics based on initial ev…

For therapies approved through expedited pathways, have follow-up trials verified the expected patient benefits, or are those benefits still being tested? [U.S]fda.govtable surrogate endpoints were basis drug approval or licensureTable of Surrogate Endpoints That Were the Basis of Drug…29 Apr 2026 — This surrogate endpoint table includes surrogate endpoints that…. Food and Drug Administration [2U.S. Food and Drug Administration]fda.govaccelerated approval programU.S. Food and Drug AdministrationAccelerated Approval Program15 May 2026 — To allow for earlier approval of drugs that treat serious cond…Published: May 2026

What are the trade-offs?

A treatment can be newer and more effective while also being more expensive, more burdensome, or associated with different risks. Improvement is rarely one-dimensional.

Skills Lab: Understanding Surrogate Endpoints and Their Limitations

Channel: Medscape · Views: 207 · Uploaded: March 2025 · Length: 10 minutes

Open on YouTube

The Real Test of Medical Progress

The history of medicine shows both remarkable innovation and recurring episodes of overconfidence. New treatments have transformed survival for many diseases, but they have done so because evidence eventually demonstrated meaningful benefits, not because they were new.

Within the appeal to novelty fallacy, the proof gap is the critical issue. Novelty can justify attention, investment, and further study. It cannot by itself justify the conclusion that a treatment is better than established care. In medicine, the decisive question is not whether an intervention is the latest option available. It is whether careful comparison shows that patients are actually better off because of it. PMC 3PMC [3eLife]whitecase.comaccelerated approval confirmatory trials requirement may further complicate lifeWhite & CaseAccelerated Approval confirmatory trials requirement may…14 Aug 2025 — Accelerated Approval allows the FDA to approve drug…

Layne Norton, PhD presentation: Common Logical Fallacies in Nutrition Science

Channel: Low Carb Conferences · Views: 4.4K · Uploaded: July 2023 · Length: 28 minutes

Open on YouTube

Amazon book picks

Further Reading

Books and field guides related to When New Treatments Outrun the Evidence. Use these as the next step if you want deeper reading beyond the article.

Browse more on Amazon: Ending Medical Reversal Testing Treatments Bad Science

As an Amazon Associate I earn from qualifying purchases.

eBay marketplace picks

Marketplace Samples

Example marketplace items related to this page. Use the search link to explore similar finds on eBay.

Using USA
Browse more on eBay.com

Example items shown for inspiration; availability and pricing can change. Branchoria may earn a commission if you purchase through outbound eBay links.

Browse more on eBay.co.uk

Example items shown for inspiration; availability and pricing can change. Branchoria may earn a commission if you purchase through outbound eBay links.

Endnotes

  1. Source: fda.gov
    Title: table surrogate endpoints were basis drug approval or licensure
    Link: https://www.fda.gov/drugs/development-resources/table-surrogate-endpoints-were-basis-drug-approval-or-licensure
    Source snippet

    Table of Surrogate Endpoints That Were the Basis of Drug...29 Apr 2026 — This surrogate endpoint table includes surrogate endpoints that...

  2. Source: pmc.ncbi.nlm.nih.gov
    Link: https://pmc.ncbi.nlm.nih.gov/articles/PMC11000139/
    Source snippet

    PMCClinical Benefit and Regulatory Outcomes of Cancer Drugs...by ITT Liu · 2024 · Cited by 135 — The US Food and Drug Administration's (...

  3. Source: nber.org
    Link: https://www.nber.org/sites/default/files/2022-09/WhitePaper-Bolder2.2019.pdf
    Source snippet

    Introduction to a New...by H Bolder · 2019 · Cited by 1 — A “medical reversal” occurs when new evidence (usually from a high-quality RCT...

  4. Source: fdli.org
    Link: https://www.fdli.org/2023/10/the-accelerated-approval-program-desiderata-for-a-proper-solution-to-the-untimely-completion-of-confirmatory-trials/
    Source snippet

    Food and Drug Law Institute (FDLI)The Accelerated Approval Program: Desiderata for a...by O Robles — Using a surrogate or intermediate c...

  5. Source: aacr.org
    Link: https://www.aacr.org/about-the-aacr/newsroom/news-releases/fewer-than-half-of-accelerated-approval-drugs-showed-clinical-benefit-in-confirmatory-trials-after-five-years/
    Source snippet

    Fewer Than Half of Accelerated Approval Drugs Showed...Apr 7, 2024 — 63% were converted to regular approval even though only 43% demonst...

  6. Source: fda.gov
    Title: accelerated approval program
    Link: https://www.fda.gov/drugs/nda-and-bla-approvals/accelerated-approval-program
    Source snippet

    U.S. Food and Drug AdministrationAccelerated Approval Program15 May 2026 — To allow for earlier approval of drugs that treat serious cond...

    Published: May 2026

  7. Source: fda.gov
    Title: accelerated approval
    Link: https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/accelerated-approval
    Source snippet

    U.S. Food and Drug AdministrationAccelerated Approval24 Feb 2023 — These regulations allowed drugs for serious conditions that filled an...

  8. Source: fda.gov
    Link: https://www.fda.gov/about-fda/oncology-center-excellence/project-confirm
    Source snippet

    U.S. Food and Drug AdministrationProject ConfirmAccelerated approval allows for earlier access to drugs and biologics based on initial ev...

  9. Source: whitecase.com
    Title: accelerated approval confirmatory trials requirement may further complicate life
    Link: https://www.whitecase.com/insight-alert/accelerated-approval-confirmatory-trials-requirement-may-further-complicate-life
    Source snippet

    White & CaseAccelerated Approval confirmatory trials requirement may...14 Aug 2025 — Accelerated Approval allows the FDA to approve drug...

  10. Source: center4research.org
    Link: https://www.center4research.org/accelerated-approval-pathway-summary/
    Source snippet

    National Center for Health ResearchFDA Accelerated Approval Pathway: Controversies and...Accelerated approval is usually based on change...

  11. Source: mayoclinicproceedings.org
    Title: This investigation sheds light on low-value practices.Read more
    Link: https://www.mayoclinicproceedings.org/article/s0025-6196%2813%2900405-9/fulltext
    Source snippet

    Mayo Clinic ProceedingsA Decade of Reversal: An Analysis of 146 Contradicted...by V Prasad · 2013 · Cited by 470 — The reversal of estab...

  12. Source: elifesciences.org
    Title: almost 400 medical practices found ineffective in analysis of 3 000 studies
    Link: https://elifesciences.org/for-the-press/94d42de3/almost-400-medical-practices-found-ineffective-in-analysis-of-3-000-studies
    Source snippet

    Almost 400 medical practices found ineffective in analysis...11 Jun 2019 — Medical reversals are practices that have been found to be no...

  13. Source: center4research.org
    Title: nchr fda confirmatory trial underway comment draft guidance
    Link: https://www.center4research.org/nchr-fda-confirmatory-trial-underway-comment-draft-guidance/
    Source snippet

    National Center for Health ResearchNational Center for Health ResearchMar 10, 2025 — The FDA should specify that confirmatory trials shou...

  14. Source: bmjopen.bmj.com
    Link: https://bmjopen.bmj.com/content/bmjopen/14/12/e085210.full.pdf
    Source snippet

    Elife 2019;8:e45183. 5 Yopes...Read more...

  15. Source: center4research.org
    Title: nchr comment accelerated approval draft guidance
    Link: https://www.center4research.org/nchr-comment-accelerated-approval-draft-guidance/
    Source snippet

    Expedited Program for Serious Conditions—Accelerated...4 Feb 2025 — The FDA draft guidance states that accelerated approval requires tha...

  16. Source: Wikipedia
    Title: Medical reversal
    Link: https://en.wikipedia.org/wiki/Medical_reversal
    Source snippet

    Medical reversalMedical reversal refers to when a newer and methodologically superior clinical trial produces results that contradict...

Additional References

  1. Source: researchgate.net
    Link: https://www.researchgate.net/publication/400519843_Evidence_Supporting_EMA_Drug_Approvals_2020-2023_A_Cross-Sectional_Study_of_Trial_Design_and_Outcomes
    Source snippet

    no evidence of superiority over active comparators, only 8%. demonstrated superiority in at least two such trials and clinical outcomes c...

  2. Source: linkedin.com
    Link: https://www.linkedin.com/pulse/accelerated-approval-updated-guidances-four-implications-sponsors-czyve
    Source snippet

    Accelerated approval updated guidancesThis pathway aims to expedite patient access to drugs for serious or life-threatening conditions by...

  3. Source: everylifefoundation.org
    Link: https://everylifefoundation.org/wp-content/uploads/2022/05/IGT-AA-Policy-Brief.pdf
    Source snippet

    FDA's Accelerated Approval PathwayApproval by the FDA is based on clinical trials that study the drug or treatment's effect on a surrogat...

  4. Source: courses.washington.edu
    Link: https://courses.washington.edu/pharm309/FlemingArticle.pdf
    Source snippet

    Endpoints And FDA's Accelerated Approval...by TR Fleming · Cited by 341 — To use surro- gate endpoints and the accelerated-approval proc...

  5. Source: parexel.com
    Link: https://www.parexel.com/insights/blog/accelerated-approval-navigating-fdas-recent-guidance-and-confirmatory-trial-considerations
    Source snippet

    Accelerated approval: Navigating FDA's recent guidance...6 Mar 2025 — This pathway aims to expedite the approval of drugs for serious or...

  6. Source: kslaw.com
    Link: https://www.kslaw.com/news-and-insights/fda-issues-draft-guidance-on-accelerated-approval-focused-on-how-the-agency-will-implement-new-authorities
    Source snippet

    FDA Issues Draft Guidance on Accelerated Approval...6 Jan 2025 — The accelerated approval program helps get necessary therapies to patie...

  7. Source: asgct.org
    Link: https://www.asgct.org/advocacy/policy-statements/expedited-program-for-serious-conditions-accelerated-approval-of-drugs-and-biologics
    Source snippet

    Expedited Program for Serious Conditions — Accelerated…6 Mar 2025 — FDA recognizes that confirmatory trial enrollment may become challeng...

  8. Source: advisory.avalerehealth.com
    Title: understanding the history and use of the accelerated approval pathway
    Link: https://advisory.avalerehealth.com/insights/understanding-the-history-and-use-of-the-accelerated-approval-pathway
    Source snippet

    the History and Use of the Accelerated...4 Jan 2022 — The Accelerated Approval Program was developed in 1992, largely in response to the...

  9. Source: pharmaphorum.com
    Title: fda accelerated approval path needs improvement says icer
    Link: https://pharmaphorum.com/news/fda-accelerated-approval-path-needs-improvement-says-icer
    Source snippet

    FDA accelerated approval path needs improvement, says...16 Apr 2026 — Accelerated approval based on surrogate or intermediate endpoint i...

  10. Source: intelacia.com
    Title: 5 fda drug approvals that could shape biotech in 2026
    Link: https://www.intelacia.com/2026/02/13/5-fda-drug-approvals-that-could-shape-biotech-in-2026/
    Source snippet

    superior weight loss at comparable doses. The company submitted its application for obesity in late 2025, and the U.S. Food and Drug...R...

Topic Tree

Follow this branch

Parent topic

Novelty Is New Always Better?

Related pages 4